Uncoupled endothelial nitric oxide synthase and oxidative stress in a rat model of pregnancy-induced hypertension.

Endothelial dysfunction and preeclampsia: role of oxidative stress. Front Physiol (2014) 1.04

Caloric restriction reverses high-fat diet-induced endothelial dysfunction and vascular superoxide production in C57Bl/6 mice. Heart Vessels (2010) 1.01

Unravelling the theories of pre-eclampsia: are the protective pathways the new paradigm? Br J Pharmacol (2015) 0.89

Nitric oxide and reactive oxygen species in the pathogenesis of preeclampsia. Int J Mol Sci (2015) 0.85

Comparison of Neurocognitive Testing and the Measurement of Marinobufagenin in Mild Traumatic Brain Injury: A Preliminary Report. J Exp Neurosci (2015) 0.76

Mechanisms of Endothelial Dysfunction in Hypertensive Pregnancy and Preeclampsia. Adv Pharmacol (2016) 0.75

Four Pathways Involving Innate Immunity in the Pathogenesis of Preeclampsia. Front Cardiovasc Med (2015) 0.75

Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia. Prog Mol Biol Transl Sci (2017) 0.75

Increased sympathetic drive during the onset of hypertension in conscious Cyp1a1-Ren2 rats. Pflugers Arch (2013) 0.75

ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation (2006) 13.21

ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol (2006) 5.70

ACC/AHA Guidelines for the Management of Patients with Peripheral Arterial Disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease)--summary of recommendations. J Vasc Interv Radiol (2006) 3.59

A nonhuman primate model of lung regeneration: detergent-mediated decellularization and initial in vitro recellularization with mesenchymal stem cells. Tissue Eng Part A (2012) 1.39

Involvement of marinobufagenin in a rat model of human preeclampsia. Am J Nephrol (2005) 1.13

Preeclampsia. Part 1: clinical and pathophysiologic considerations. Obstet Gynecol Surv (2002) 1.11

Characterization of the isozymes of pyruvate dehydrogenase phosphatase: implications for the regulation of pyruvate dehydrogenase activity. Biochim Biophys Acta (2003) 1.04

FK506 binding protein 12/12.6 depletion increases endothelial nitric oxide synthase threonine 495 phosphorylation and blood pressure. Hypertension (2007) 0.99

A rat model of preeclampsia. Clin Exp Hypertens (2005) 0.98

Examination of the cellular mechanisms by which marinobufagenin inhibits cytotrophoblast function. J Biol Chem (2008) 0.94

Removal of FKBP12/12.6 from endothelial ryanodine receptors leads to an intracellular calcium leak and endothelial dysfunction. Arterioscler Thromb Vasc Biol (2007) 0.94

Resibufogenin corrects hypertension in a rat model of human preeclampsia. Exp Biol Med (Maywood) (2006) 0.92

Preeclampsia. Part 2: experimental and genetic considerations. Obstet Gynecol Surv (2002) 0.88

Marinobufagenin is an upstream modulator of Gadd45a stress signaling in preeclampsia. Biochim Biophys Acta (2010) 0.85

Pharmacological inhibition of HDAC6 attenuates endothelial barrier dysfunction induced by thrombin. Biochem Biophys Res Commun (2011) 0.84

Marinobufagenin causes endothelial cell monolayer hyperpermeability by altering apoptotic signaling. Am J Physiol Regul Integr Comp Physiol (2009) 0.82

Vascular leak in a rat model of preeclampsia. Am J Nephrol (2009) 0.81

Resibufogenin administration prevents oxidative stress in a rat model of human preeclampsia. Hypertens Pregnancy (2010) 0.80

Probing a putative active site of the catalytic subunit of pyruvate dehydrogenase phosphatase 1 (PDP1c) by site-directed mutagenesis. Biochim Biophys Acta (2004) 0.79

Resibufogenin prevents the manifestations of preeclampsia in an animal model of the syndrome. Hypertens Pregnancy (2010) 0.79

A chemifluorescent immunoassay for the determination of marinobufagenin in body fluids. J Immunoassay Immunochem (2011) 0.79

Marinobufagenin interferes with the function of the mineralocorticoid receptor. Biochem Biophys Res Commun (2007) 0.78

Marinobufagenin levels in preeclamptic patients: a preliminary report. Am J Perinatol (2011) 0.78

Genetic variation in solute carrier genes is associated with preeclampsia. Am J Obstet Gynecol (2010) 0.78

Phenotypic characteristics shared by preeclamptic patients and an animal model of the syndrome: report of a pilot study. Am J Hypertens (2006) 0.78

Alterations in the renin-angiotensin system in a rat model of human preeclampsia. Am J Nephrol (2009) 0.77

Beneficial effects of metolazone in a rat model of preeclampsia. J Pharmacol Exp Ther (2006) 0.77

62-year-old-female with weakness and shortness of breath. Am J Med Sci (2009) 0.75

A 73-year-old-man with fever and weight loss. Am J Med Sci (2010) 0.75